{
  "docId": "019de076-a4b3-719a-94d2-ca29be1b4679",
  "docSlug": "0f14c676100503df3bb87c658cc9d332",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 26,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a comparative structure to highlight the superiority of alpha particles in DNA damage and clinical logistics.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-a4b3-719a-94d2-ca29be1b4679/11",
  "deckHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679",
  "deckJsonHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679.json",
  "deckAnchorHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.75,
        "y": 0.3
      },
      "kind": "image",
      "text": "Diagram showing Ac-225 decay chain causing DNA double-strand breaks in a cancer cell",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61af8f73-40d5-4fea-9ee9-f7e83c1090aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.38,
        "y": 0.25
      },
      "kind": "list",
      "text": "10-day half-life; Multiple alpha particles; Superiority in preclinical data; High-level clinical trial safety",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22f03744-8b8f-4004-8971-9a8ebe3ba0dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Double vs single strand DNA breaks; Shorter range/higher energy; Strong immune response; Active in hypoxic tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70903aaf-e646-46c3-8c4f-496acb5ce4b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.35,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Pouget J-P and Constanzo J (2021) Revisiting the Radiobiology of Targeted Alpha Therapy. Front. Med. 8:692436. doi: 10.3389/fmed.2021.692436",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2842d600-f06e-4932-ae4e-2933555a702e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Alpha-Emitting Radioisotopes Represent the Future of Radiopharma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de547b54-ff8f-4334-9056-fb629597a281",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 11,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5a525fa2-3a5d-4e7d-9581-137e28735da1",
      "evidence": "The document presents information on the future of radiopharma and the potential of alpha-emitting radioisotopes",
      "position": 0,
      "objective": "Highlight the importance of alpha-emitting radioisotopes in radiopharma",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}